.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The US Department of Health and Human Services (HHS) recently announced a formal search for new nominees. This move aims to revitalize the Preventive Services Task Force, which has remained inactive for over a year. Consequently, Secretary Robert F. Kennedy Jr. expressed serious concerns regarding the panel's recent performance. He described the current state of the task force as lackadaisical during a House committee hearing earlier this month. Moreover, the delay in appointing new members has stalled vital updates for clinical practice.
This influential panel determines which medical screenings are provided at no cost to patients. However, the task force has not met for more than twelve months. Because of this gap, five volunteer terms expired without any immediate replacements. New nominations are now being accepted through May 23. Furthermore, the agency seeks experts in oncology, cardiology, pediatrics, and health economics. Clinicians in these fields play a vital role in shaping preventive care frameworks.
Medical experts warn that sidelining this panel carries significant risks. Specifically, it delays critical updates to cancer and heart disease screening guidelines. Since these standards influence global practices, clinicians in various regions must stay informed. Additionally, the HHS emphasizes the need for diverse expertise to fill these roles. The involvement of family medicine and obstetrics specialists remains a top priority for the department.
Q1: Why are new members being sought for the task force?
Terms for five previous volunteers expired, and the panel has not met for over a year, causing a backlog in screening updates.
Q2: Which specialties are eligible for nomination to the panel?
The HHS is seeking clinicians and researchers in cardiology, oncology, pediatrics, family medicine, and health economics, among others.
Q3: How does this panel affect patient care costs?
The task force decides which preventive medical services must be provided to patients at no cost under insurance coverage rules.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
US HHS Secretary RFK Jr. calls for new nominees for the Preventive Services Task Force to address delays in cancer and heart disease screening guidelines....
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
